LifeBank

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, January 11, 2023
Gulf Cooperation Council, Degenerative disease, LifeBank, Umbilical cord, Vision 2030, Public health, Organisation of Islamic Cooperation, Trauma, Partner (business rank), Health, CELU, Therapy, CH, Placenta, Research, Wound healing, Islamic marketing, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., African Union, Pakistan and the Organisation of Islamic Cooperation, Organization, United Arab Emirates, Silk, Weapon, Medical device, Kingdom, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer"). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.

Key Points: 
  • Tamer Group will be the exclusive distributor of the Celularity branded biomaterial products in Saudi Arabia, opening access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products
    FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia, Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer").
  • The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.
  • "Saudi Arabia is a prime market for Celularity's commercial regenerative biomaterial products," said CEO of CH Trading Group, Sayed Zayan.
  • "We are excited to partner with Tamer Group and to be a part of fulfilling their commitment to the development of the Kingdom's healthcare sector."

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, January 11, 2023
Gulf Cooperation Council, Degenerative disease, LifeBank, Umbilical cord, Vision 2030, Public health, Organisation of Islamic Cooperation, Trauma, Partner (business rank), Health, CELU, Therapy, CH, Placenta, Research, Wound healing, Islamic marketing, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., African Union, Pakistan and the Organisation of Islamic Cooperation, Organization, United Arab Emirates, Silk, Medical device, Kingdom, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia , Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer"). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.

Key Points: 
  • Tamer Group will be the exclusive distributor of the Celularity branded biomaterial products in Saudi Arabia, opening access to Celularity's Halal-Certified regenerative biomaterial, health and wellness products
    FLORHAM PARK, N.J, RIYADH, Saudi Arabia and JEDDAH, Saudi Arabia , Jan. 11, 2023 /PRNewswire/ -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer").
  • The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia.
  • "Saudi Arabia is a prime market for Celularity's commercial regenerative biomaterial products," said CEO of CH Trading Group, Sayed Zayan.
  • "We are excited to partner with Tamer Group and to be a part of fulfilling their commitment to the development of the Kingdom's healthcare sector."

Huawei set to bring connectivity to 120m people in rural areas worldwide

Retrieved on: 
Thursday, November 24, 2022
Digital technology, Blood, Hospital, Connectivity, GSMA, SME, Multimedia, SPARK (programming language), LifeBank, Intelligence, Internet, Mobile phone, Huawei

Liang Hua, chairman of Huawei, said in the intelligent era, connectivity will be more than just a tool for convenient communications.

Key Points: 
  • Liang Hua, chairman of Huawei, said in the intelligent era, connectivity will be more than just a tool for convenient communications.
  • Together with digital technologies like cloud and artificial intelligence, connectivity will help bring everyone into the digital world and drive social progress.
  • According to the GSMA's Mobile Economy Report 2022, only 6 percent of the world's population live in areas without mobile network coverage.
  • "As digital technology enables more industries to go digital, the digital economy is becoming increasingly integrated with the real economy.

$2.83 Billion Worldwide Cord Blood Banking Services Industry to 2027 - Featuring Alphacord, Americord Registry, ATCC and California Cryobank Among Others

Retrieved on: 
Monday, October 24, 2022
Leukemia, Placenta, Cord blood, Therapy, Prevalence, B cell, Lymphoma, Red blood cell, Smoking, LifeBank, CAGR, Patient, Hospital, Research, Collection, Cancer, Lists of diseases, Bone marrow, R, Industry, Stem cell, Awareness, PerkinElmer, White blood cell, Umbilical cord, COVID-19, ATCC, Hematology, Pharmaceutical industry, Cryptocurrency, Potash, California Cryobank, Growth

The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021.

Key Points: 
  • The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021.
  • Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.
  • Moreover, there is an increase in the utilization of cord blood banking services for the treatment of immunodeficiency disorders across the globe.
  • What is the structure of the global cord blood banking services market and who are the key players?

LifeBank Chain Brings Ultimate Gene and Cell Therapy Benefits to Everyone

Retrieved on: 
Wednesday, January 12, 2022
Medicine, LifeBank, News, Longevity, LBC, Gene, Disease, Solution, GLOBE, Genetics, Cancer, Immune system, Blood, Immunotherapy, Cell, Workflow, Vaccine

JERUSALEM, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Recently, a start-up project "LifeBank Chain (LBC)" in Israel is utilizing advanced gene and cell technologies over blockchain to develop advanced therapies.

Key Points: 
  • JERUSALEM, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Recently, a start-up project "LifeBank Chain (LBC)" in Israel is utilizing advanced gene and cell technologies over blockchain to develop advanced therapies.
  • They endeavor to further human longevity and expand access to genetics and cell treatments through cutting-edge technologies.
  • Gene therapy involves altering the genes inside human body's cells in an effort to treat or stop disease.
  • Gene therapy is the introduction of genes into existing cells to prevent or cure a wide range of diseases.

LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies

Retrieved on: 
Friday, December 31, 2021
Attention, Disease, Inflammation, Cancer, Blockchain, CELL, Genetics, Health, GLOBE, LBC, LifeBank, Medicine, Research, Parent, Workflow, Genetic, Autoimmune disease, Patient, Technology, Vaccine, Cryptocurrency

JERUSALEM, Dec. 31, 2021 (GLOBE NEWSWIRE) -- GENE & CELL MEDICINE LTD located in Israel and Singapore started a new project :LifeBank Chain (LBC).

Key Points: 
  • JERUSALEM, Dec. 31, 2021 (GLOBE NEWSWIRE) -- GENE & CELL MEDICINE LTD located in Israel and Singapore started a new project :LifeBank Chain (LBC).
  • The project LBC plans to build a genetic and cell data collaboration platform.
  • LBC plans to build a genetic and cell data collaboration platform incorporating an extensible cross-chain service system based on individual and institutional nodes.
  • The platform product service layer abstracts all typical kinds of gene and cell blockchain applications and provides the full functions and implementation framework of typical applications.

EOS Costa Rica Leverages Blockchain to Tackle a Global Blood Supply Shortage Amid the COVID-19 Pandemic

Retrieved on: 
Thursday, July 30, 2020
Data management, Technology, Other Health, Health, General Health, Security, Other Technology, Infectious diseases, Software, Hospitals, Internet, Cryptocurrencies, LifeBank, EOS.IO, EOSIO, EOS Costa Rica

EOS Costa Rica is leveraging EOS.IO, an open-source blockchain protocol, to deploy Lifebank, an incentive-based healthcare solution for blood donations, to help solve a global blood shortage caused by COVID-19.

Key Points: 
  • EOS Costa Rica is leveraging EOS.IO, an open-source blockchain protocol, to deploy Lifebank, an incentive-based healthcare solution for blood donations, to help solve a global blood shortage caused by COVID-19.
  • The coronavirus pandemic is firmly cemented as the second-worst pandemic in U.S. history, trailing only the Spanish Flu.
  • In March, the Red Cross canceled 2,700 blood drives, resulting in 86,000 fewer blood donations - an 80% decline.
  • EOS Costa Rica co-founder, Edgar Fernandez, explained, The coronavirus pandemic uncovered a number of problem areas in the healthcare supply chain - one of which being blood donations.